 Clene Nanomedicine

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced that CNM-Au8® results in multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) were presented in plenary sessions at the 2023 American Academy of Neurology (AAN) Annual Meeting, currently taking place in Boston. The MS platform presentation and ALS survival poster highlight the results from multiple clinical trials that demonstrated clinical benefit and safety of treatment with CNM-Au8, a cellular energetic nanocatalyst.

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced three presentations at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, taking place April 22-27, 2023, in Boston, MA. The platform presentations and poster highlight the results from three clinical trials that demonstrated clinical benefit and safety of treatment with CNM-Au8®.

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

NEW YORK , March 20, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Clene Inc. (NASDAQ: CLNN). If you are a shareholder of Clene Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/clene-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Clene Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Here is how Clene Inc. (CLNN) and The Cooper Companies (COO) have performed compared to their sector so far this year.

Is Clene (CLNN) Stock Outpacing Its Medical Peers This Year?

SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.

Clene Appoints Neurology Expert to Executive Team

SALT LAKE CITY, March 13, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its full year 2022 financial results and provided recent operating highlights for the clinical programs in ALS and MS.

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Clene will host a live audio webcast at 7:30 a.m. EST today to review these new clinical results.

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will participate in Roth's 35th Annual Healthcare Conference set for March 12th-14th and in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow Series on March 7th and 22nd.

Clene Nanomedicine to Participate in Roth's 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

Vallon Pharmaceuticals

Wish

Use these tips for analyzing penny stocks in 2023 The post How to Analyze Penny Stocks for Profits  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Analyze Penny Stocks for Profits

SALT LAKE CITY, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple sclerosis (MS) patients. These exploratory MRI results support the previously reported statistically significant clinical improvements in low contrast vision and global neurological function in stable relapsing MS patients reported in the mITT population.

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow Series on January 18 and January 23. The Company welcomes stakeholders, investors, and other interested parties to register and attend these free live events.

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

Aziyo Biologics, Inc

Cadiz

Cognition Therapeutics

Eterna Therapeutics Inc

HireRight GIS Group Holdings LLC

Dave & Buster's

Rain Therapeutics

Tenaya Therapeutic

The Fintel Insider Sentiment quant model identifies US stocks that have experienced significant insider buying activity over the last 90 days.

These 10 Stocks Had the Most Insider Buying Activity During the December Quarter

SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19.

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor Hogan

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

Clene Inc. (CLNN) delivered earnings and revenue surprises of 39.13% and 228.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Clene Inc. (CLNN) Reports Q3 Loss, Tops Revenue Estimates

SALT LAKE CITY, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its third quarter 2022 financial results and recent operating highlights.

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

Clene Inc. (CLNN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clene Inc. (CLNN) Expected to Beat Earnings Estimates: Should You Buy?

SALT LAKE CITY, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced topline study results showing a survival benefit in the Healey ALS Platform trial of CNM-Au8®, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis (ALS).

Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

Adverum Biotechnologies

Spero Therapeutics

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Conference Call and Webcast Set for 8:30 a.m. EDT Conference Call and Webcast Set for 8:30 a.m. EDT

Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

SALT LAKE CITY, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced presentation of updated survival results from the Phase 2 RESCUE-ALS trial open-label extension (OLE) at the 2022 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Clinical & Scientific Conference, taking place September 21-24 in Nashville, Tennessee.

Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc.  (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will participate in the following investor conferences in September:

Clene to Present at Upcoming September Investor Conferences

SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced positive topline results from the Phase 2 VISIONARY-MS trial of CNM-Au8®, an investigational gold nanocrystal suspension, in participants with stable relapsing remitting multiple sclerosis (RRMS).

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its second quarter 2022 and recent operating highlights.

News for Clene Nanomedicine Stock (CLNN)